Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides: In Vitro and in Vivo Activities and Mechanisms

Annals of the New York Academy of Sciences

Volumn 1002, Issue , 2003, Pages 217-235

  Wang, Hui ^a   Oliver, Patsy ^a   Zhang, Zhuo ^a   Agrawal, Sudhir ^b   Zhang, Ruiwen ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HYBRIDON INC   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Human cancer xenograft; Irinotecan; p53; Paclitaxel

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PROTEIN MDM2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CARCINOGENICITY; CONFERENCE PAPER; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SPECIFICITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RADIOSENSITIZATION; TUMOR REGRESSION;

MUS MUSCULUS;

EID: 1342332342     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1281.025     Document Type: Conference Paper

References (140)

1. HANAHAN, D. & R.A. WEINBERG. 2000. The hallmarks of cancer. Cell 100: 57-70.
2. ZAKUT-HOURI, R. et al. 1983. Human P53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 4: 1251-1255.
3. PRIVES, C. & P.A. HALL. 1999. The p53 pathway. J. Pathol. 187: 112-126.
4. FREEDMAN, D.A. & A.J. LEVINE. 1999. Regulation of the p53 protein by the MDM2 oncoprotein - Thirty-eighth G.H.A. Clowes Memorial Award lecture. Cancer Res. 59: 1-7.
5. HUPP, T.R. et al. 2000. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352: 1-17.
6. WOODS, D.B. & K.H. VOUSDEN. 2001. Regulation of p53 function. Exp. Cell Res. 264: 56-66.
7. LANE, D.P. & S. LAIN. 2002. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8: S38-S42.
8. MICHAEL, D. & M. OREN. 2002. The p53 and MDM2 families in cancer. Curr. Opin. Genet. Dev. 12: 53-59.
9. HOLLSTEIN, M.D. et al. 1991. p53 mutations in human cancers. Science 253: 49-53.
10. HAINAUT, P. et al. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25: 151-157.
11. SLINGERLAND, J.M. et al. 1991. Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77: 1500-1507.
12. BARTEK, J. et al. 1990. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-899.
13. SAITOH, S. et al. 1994. P53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9: 2869-2875.
14. AKSLEN, L.A. & O. MORKVE. 1992. Expression of p53 protein in cutaneous melanoma. Intl. J. Cancer 52: 13-16.
15. KOVACH, J.S. et al. 1996. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 93: 1093-1096.
16. SILVESTRINI, R. et al. 1996. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin. Cancer Res. 2: 2007-2013.
17. SLATON, J.W. et al. 2001. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57: 852-859.
18. WELLER, M. 1998. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292: 435-445.
19. KASTAN, M.B. et al. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
20. DI LEONARDO, A. et al. 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Gene Dev. 8: 2540-2551.
21. LANG, F.F. et al. 1998. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurg. 89: 125-132
22. MUSCHEL, R.J. et al. 1998. Radiosensitization and apoptosis. Oncogene 17: 3359-3363.
23. COWEN, D. et al. 2000. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin. Cancer Res. 6: 4402-4408.
24. COLLETIER, P.J. et al. 2000. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int. J. Radiat. Oncol. Biol. Phys. 48: 1507-1512.
25. KUERBITS, S.J. et al. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491-7495.
26. Wu, X. et al. 1993. The p53-mdm2 autoregulatory feedback loop. Genes Dev. 7: 1126-1132.
27. FORNACE, A.J., JR. et al. 1989. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell Biol. 9: 4196-4203.
28. EL-DEIRY, W.S. et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54: 1169-1174.
29. O'CONNOR, P.M. et al. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300.
30. BAKER, S.J. et al. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
31. DORIGO, O. et al. 1998. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J. Neurosurg. 88: 535-540.
32. NIELSEN, L.L. & D.C. MANEVAL. 1998. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5: 52-63.
33. SPITZ, F.R. et al. 1996. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 2: 1665-1671.
34. HWANG, R.F. et al. 1998. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 124: 143-150.
35. NIELSEN, L.L. et al. 1998. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4: 835-846.
36. HEISE, C. et al. 2000. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. 6: 4908-4914.
37. MIYAKE, H. et al. 2000. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. Urology 56: 332-336.
38. NISHIZAKI, M. et al. 2001. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin. Cancer Res. 7: 2887-2897.
39. KAWABE, S. et al. 2001. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int. J. Radiat. Biol. 77: 185-194.
40. MODESITT, S.C. et al. 2001. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin. Cancer Res. 7: 1765-1772.
41. SEKI, M. et al. 2002. p53 and PTEN/MMAC1/TEP1 Gene therapy of human prostate pc-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum. Gene Ther. 13: 761-773.
42. MOMAND, J. et al. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26: 3453-3459.
43. MOMAND, J. et al. 2000. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242: 15-29.
44. ZHANG, R. & H. WANG. 2000. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Design 6: 393-416.
45. FAKHARZADEH, S.S. et al. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565-1569.
46. LUNDGREN, K. et al. 1997. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11: 714-725.
47. MCCANN, A.H. et al. 1995. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer 71: 981-985.
48. MARCHETTI, A. et al. 1995. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol. 175: 31-38.
49. CUNY, M. et al. 2000. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 60: 1077-1083.
50. JIANG, M. et al. 1997. P21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer. (Pred. Oncol.) 74: 529-534.
51. VALASSIADOU, K.E. et al. 1997. Immunohistochemical expression of p53, bcl-2, mdm2, and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res. 17: 2571-2576.
52. SHIMADA, Y. et al. 1997. Genetic alterations in patients with esophageal cancer with short-and long-term survival rates after curative esophagectomy. Ann. Surg. 226: 162-168.
53. EHRMANN, J., JR. et al. 1997. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2, and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304.
54. OSMAN, I. et al. 1997. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Clin. Cancer Res. 3: 531-536.
55. WURL, P. et al. 1998. Significance of retinoblastoma and MDM2 gene expression as prognostic markers for soft-tissue sarcoma. Langenbecks Arch. Surg. 383: 99-103.
56. SHIINA, H. et al. 1999. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 56: 239-247.
57. MOLINA, P. et al. 1999. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. Virchows Arch. 435: 596-605.
58. OSMAN, I. et al. 1999. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res. 5: 2082-2088.
59. SOSLOW, R.A. et al. 1999. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod. Pathol. 12: 580-586.
60. MOLLER, M.B. et al. 1999. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod. Pathol. 12: 1010-1016.
61. WURL, P. et al. 2000. A multifactorial prognostic model for adult soft tissue sarcoma considering clinical, histopathological and molecular data. Anticancer Res. 20: 2065-2072.
62. COUPLAND, S.E. et al. 2000. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J. Pathol. 191: 120-126.
63. FADERL, S. et al. 2000. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 89: 1976-1982.
64. ZHOU, M. et al. 2000. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14: 61-67.
65. ENDO, K. et al. 2000. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 20: 209-215.
66. MULLER-HOCKER, J. et al. 2001. Deregulated expression of cell cycle-associated proteins in solid pseudopapillary tumor of the pancreas. Mod. Pathol. 14: 47-53.
67. PAGNANO, K.B. et al. 2001. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am. J. Hematol. 67: 84-92.
68. WATANABE, T. et al. 2001. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology 39: 187-197.
69. UCHIDA, T. et al. 2002. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 59: 615-620.
70. LU, M.L. et al. 2002. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res. 8: 171-179.
71. BURTON, E.C. et al. 2002. Aberrant p53, MDM2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin. Cancer Res. 8: 180-187.
72. OZDEMIR, E. et al. 1997. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J. Urol. 158: 206-211.
73. TRONCONE, G. et al. 1998. Immunohistochemical expression of MDM2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection. J. Clin. Pathol. 51: 754-760.
74. POLSKY, D. et al. 2001. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 61: 7642-7646.
75. DATTA, M.W. et al. 2001. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of MDM2 expression. Mod. Pathol. 14: 437-42.
76. LEITE, K.R. et al. 2001. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 14: 428-436.
77. LUKAS, J. et al. 2001. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61: 3212-3219.
78. QIU, S.J. et al. 1998. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 124: 253-258.
79. HORIE, S. et al. 2000. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch. 437: 25-30.
80. LOPES, M.A. et al. 2001. Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws. Oral Oncol. 37: 566-571.
81. PFISTER, C. et al. 1999. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res. 5: 4079-4084.
82. GANLY, I. et al. 2000. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br. J. Cancer 82: 392-398.
83. EID, H. et al. 1999. mdm-2 expression in human testicular germ-cell tumors and its clinical value. Anticancer Res. 19: 3485-3490.
84. BROLL, R. et al. 1999. Expression of p53 and MDM2 mRNA and protein in colorectal carcinomas. Eur. J. Cancer 35: 1083-1088.
85. ABDEL-FATTAH, G. et al. 2000. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J. Gastrointest. Surg. 4: 109-114.
86. HAITEL, A. et al. 2000. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 6: 1840-1844.
87. FORUS, A. et al. 2001. Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet. Cytogenet. 125: 100-111.
88. MATHEW, R. et al. 2002. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur. J. Cancer 38: 832-841.
89. BARAK, Y. et al. 1993. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
90. MOMAND, J. et al. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
91. CHEN, C.Y. et al. 1994. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 91: 2684-2688.
92. CHEN, J. et al. 1996. MDM2 inhibits the Gl arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16: 2445-2452.
93. HAUPT, Y. et al. 1997. MDM2 promotes the rapid degradation of p53. Nature 387: 296-299.
94. KUBBUTAT, M.H.G. et al. 1997. Regulation of p53 stability by mdm2. Nature 387: 299-303.
95. KAMIJO, T. et al. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and MDM2. Proc. Natl. Acad. Sci. USA 95: 8292-8297.
96. BOTHNER, B. et al. 2001. Defining the molecular basis of Arf and Hdm2 interactions. J. Mol. Biol. 314: 263-277.
97. XIAO, Z. et al. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
98. MARTIN, K. et al. 1995. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
99. MARECHAL, V. et al. 1994. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14: 7414-7420.
100. ELENBAAS, B. et al. 1996. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2: 439-451.
101. GANGULI, G. et al. 2000. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 19: 5135-5147.
102. TEOH, G. et al. 1997. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90: 1982-1992.
103. JONES, S.N. et al. 1998. Overexpression of Mdm2 in mice reveals a p53-independent role for MDM2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 95: 1508-1512.
104. PENG, Y. et al. 2001. Stabilization of the MDM2 oncoprotein by mutant p53. J. Biol. Chem. 276: 6874-6878.
105. PAN, Y. & D.S. HAINES. 1999. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res. 59: 2064-2067.
106. KONDO, S. et al. 1995. M2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006.
107. KONDO, S. et al. 1996. MDM2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br. J. Cancer 74: 1263-1268.
108. SUZUKI, A. et al. 1998. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn. J. Cancer Res. 89: 221-227.
109. MORGAN, S.E. et al. 2000. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene 19: 5010-5019.
110. Gu, L. et al. 2002. MDM2 induces NF-kappaB/p65 expression transcriptionally through Spl-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99: 3367-3375.
111. COCKER, H.A. et al. 2001. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br. J. Cancer 85: 1746-1752.
112. KESHELAVA, N. et al. 2001. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61: 6185-6193.
113. YAZLOVITSKAYA, E.M. et al. 2001. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem. Biophys. Res. Commun. 283: 732-737.
114. SUN, P. et al. 1998. p53-independent role of MDM2 in TGF-beta1 resistance. Science 282: 2270-2272.
115. CHEN, L. et al. 1998. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95: 195-200.
116. WANG, H. et al. 1999. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol. 15: 653-660.
117. CHEN, L. et al. 1999. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5: 21-34.
118. ZAMECNIK, P.C. 1996. History of antisense oligonucleotides. In Antisense Therapeutics. S. Agrawal, Ed.: 1-12. Humana Press. Totowa, NJ.
119. DIASIO, R.B. & R. ZHANG. 1997. Pharmacology of therapeutic oligonucleotides antisense nucleic acid. Drug Dev. 7: 239-243.
120. WICKSTROM, E. 1998. Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Marcel Dekker. New York.
121. JEN, K.Y. & A.M. GLWIRTZ. 2000. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 18: 307-319.
122. PHILLIPS, M.I., Ed. 2000. Antisense Technology, Part B: Applications. Methods in Enzymology 314. Academic Press. San Diego, CA.
123. CROOKE, S.T. 2001. Antisense Drug Technology. Principles, Strategies, and Applications. Marcel Dekker. New York.
124. Wang, H. et al. 2001. Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 1: 177-196.
125. AGRAWAL, S. & E.R. KANDIMALLA. 2001. Antisense and/or immunostimulatory oligonucleotide therapeutics. Cancer Drug Targets 1: 197-209.
126. LUGER, S.M. et al. 2002. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99: 1150-1158.
127. AGRAWAL, S. et al. 1997. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94: 2620-2625.
128. AGRAWAL, S. et al. 1997. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 7: 245-249.
129. AGRAWAL, S. & R. ZHANG. 1997. Pharmacokinetics of phosphorothioate oligonucleotide and its novel analogs. In Antisense Oligodeoxynucleotides and Antisense: RNA as Novel Pharmacological and Therapeutic Agents. B. Weiss, Ed.: 58-78. CRC Press.
130. AGRAWAL, S. & R. ZHANG. 1997. Pharmacokinetics of oligonucleotides. In Oligonucleotides as Therapeutic agents. Ciba Found. Symp. 209: 60-78. Wiley. Chichester, UK.
131. AGRAWAL, S. & R. ZHANG. 1997. Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administrations in experimental animals. In Antisense Research and Applications. S. Crooke, Ed.: 25-543. Springer-Verlag. Heidelberg.
132. WANG, H. et al. 1999. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96: 13989-13994.
133. WANG, H. et al. 2001. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7: 3613-3624.
134. WANG, H. et al. 2002. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Intl. J. Oncol. 20: 745-752.
135. PRASAD, G. et al. 2002. Antisense anti-MDM2 oligonucleotides as a novel spproach to the treatment of glioblastoma multiforme. Anticancer Res. 22: 107-116.
136. ZHANG, R. & H. WANG. 2002. Modulation of gene expression by antisense olingonucleotides. In Pharmaceutical Pespectives of Nucleic Acid-based Therapeutics. S.W. Kim & R.I. Mahato, Eds.: 33-53. Harwood Academic Publishers.
137. WANG, H. et al. 2002. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-Dependent and p53-independent mechanisms. Mol. Med. 8: 184-198.
138. WANG, H. et al. 2003. Experimental therapy of human prostate cancer by inhibiting mdm2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54: 194-205.
139. ZHANG, R. & H. WANG. 2003. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol. Med. 85: 205-222.
140. th Annual Meeting AACR 44: 1021.